Skip to main content

Advertisement

Table 6 Patients’ characteristics

From: Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients

  Age Gender Tumor size (mm) CEA CA 19-9 T N LNR Margin (mm) Differ Vasc invas G
LongS 1 70 F 50 8 52.3 3 1 1/57 2 W No IIB
LongS 2 70 M 25 2.1 202.56 3 0 0/21 1 M-P No IIA
LongS 3 63 M 35 2 200 4 0 0/16 3 M Vein III
LongS 4 66 F 50 1.1 1007 3 1 8/65 0 W-M Vein IIB
LongS 5 59 M 40 NA NA 4 1 4/39 3 W-M No III
LongS 6 76 M 40 1.8 43.2 3 1 3/25 2 P Vein IIB
LongS 7 67 F 60 3.6 1626 3 1 4/43 3 M No IIB
LongS 8 69 F 25 1.4 220.4 3 0 0/16 3 M No IIA
ShortS 1 47 M 40 NA 112 3 1 6/64 2 P No IIB
ShortS 2 65 M 30 144 97.4 3 1 5/83 2 P No IIB
ShortS 3 78 F 30 3.6 250 3 1 NA 2 M No IIB
ShortS 4 72 F 35 2 13 3 1 NA 0 M-P No IIB
ShortS 5 82 F 25 NA 178 3 0 0/18 0 W Vein IIA
ShortS 6 49 F 30 2.3 451.5 3 1 6/42 1 P Vein IIB
ShortS 7 62 M 70 4.5 293.7 4 1 1/36 0 W Vein III
ShortS 8 60 M 40 4.2 916 3 1 18/33 0 Coll Vein IIB
ShortS 9 61 F 30 4.7 246.4 3 1 2/38 0 M Vein IIB
  1. Seventeen samples from 17 patients with PA: 8 patients were classified as long-term survival patients (>3 years), while the 9 others had a short-term survival (<1 year). There was no significant difference in terms of T stage (p = 0.453), N+ status (p = 0.2), differentiation (p = 0.481), CA 19-9 (p = 0.236), or CEA (p = 0.322). There was a significantly larger resection margin in long-term survivors (2.13 mm vs 0.78 mm; p = 0.018). LongS long-term survival patients, ShortS short-term survival patients, CEA carcinoembryonic antigen, NA not available, CA 19-9 carbohydrate antigen 19-9. T and N describing the tumor/node/metastasis: T tumor, N lymph nodes; LNR lymph node ratio, Differ differentiation, W well-differentiated, P poorly differentiated, M moderately differentiated, Coll colloid, Vasc invas vascular invasion, G grading